US6753013B1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
US6753013B1
US6753013B1 US09/959,367 US95936701A US6753013B1 US 6753013 B1 US6753013 B1 US 6753013B1 US 95936701 A US95936701 A US 95936701A US 6753013 B1 US6753013 B1 US 6753013B1
Authority
US
United States
Prior art keywords
composition
dihydroxy
component
composition according
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/959,367
Other languages
English (en)
Inventor
Erik Didriksen
Gert Høy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharmaceutical Products Ltd AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8094933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6753013(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A10-cv-00269 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A20-cv-01359 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in New York Southern District Court litigation https://portal.unifiedpatents.com/litigation/New%20York%20Southern%20District%20Court/case/1%3A11-cv-00963 Source: District Court Jurisdiction: New York Southern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharmaceutical Products Ltd AS filed Critical Leo Pharmaceutical Products Ltd AS
Assigned to LEO PHARMACEUTICAL PRODUCTS LTD. A/S reassignment LEO PHARMACEUTICAL PRODUCTS LTD. A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DIDRIKSEN, ERIK, HOY, GERT
Application granted granted Critical
Publication of US6753013B1 publication Critical patent/US6753013B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention concerns pharmaceutical compositions for dermal use which contain at least one vitamin D or vitamin D analogue and at least one corticosteroid. More specifically, the invention relates to pharmaceutical compositions containing two or more pharmacologically active compounds which have low compatibility with respect to the pH value of optimum stability, preferably, said pharmacologically active compounds are at least one vitamin D analogue and at least one corticosteroid.
  • a combination treatment incorporating two or even more different pharmacologically active compounds.
  • a combination treatment involving a steroid compound, such as a corticosteroid compound, and a vitamin D analogue such as calcipotriol, and where each of the active compounds are formulated in separate preparations.
  • the following example describes the difficulties encountered when the skilled person wishes to prepare a combination composition for topical use comprising both a vitamin D or a vitamin D analogue or derivative and a topical steroid:
  • the vitamin D analogue calcipotriol, as well as other examples of vitamin D analogues, requires a pH value above 8 for maximum stability, whereas corticosteroids such as Betamethasone (9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione) require pH values in the range of 4-6 for maximum stability.
  • the provision of said composition will result in a substantial improvement in quality of life for a large population of psoriasis patients, especially the noncompliant group having a higher self-rated severity of psoriasis, being younger, and having a younger age at onset than those who are compliant.
  • the invention provides a pharmaceutical composition for dermal use, said composition comprising a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue and a second pharmacologically active component B consisting of at least one corticosteroid.
  • vitamin D analogues selected from the group consisting of calcipotriol, calcitriol, tacalcitol, maxacalcitol, and 1(S),3(R)-dihydroxy-20(R)-[((3(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene as well as mixtures thereof.
  • Synthetic vitamin D analogues are more preferred in the compositions according to the invention than naturally occurring vitamin D's or vitamin D derivatives, since the therapeutic effects of the latter may be less selective for the treatment of skin diseases, such as psoriasis.
  • vitamin D compounds constituting the first pharmacologically active component A are:
  • Component B is preferably selected from the group consisting of Betamethasone (9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione) and esters thereof such as the 21-acetate, 17-adamantoate; 17-benzoate, 17-valerate, and 17,21-dipropionate; Alclomethasone and esters thereof such as the dipropionate; Clobetasole and esters thereof such as the propionate; Clobetasone and esters thereof such as the 17-butyrate; Desoximetasone; Diflucortolon and esters thereof, Diflorasone and esters thereof such as the diacetate; Fluocinonid; Flumetasone and esters thereof such as the pivalate; Fluocinol
  • corticosteroids are Betamethasone or esters thereof such as the 17-valerate or the 17,21-dipropionate, Clobetasole or esters thereof such as the propionate, Triamcinolon or ethers and/or thereof such as the acetonide or the acetonide-21-N-benzoyl-2-methyl- ⁇ -alaninate or the acetonide-21-(3,3-dimethylbutyrate), or Hydrocortisone or esters thereof such as the 17-butyrate.
  • Betamethasone or esters thereof such as the 17-valerate or the 17,21-dipropionate
  • Clobetasole or esters thereof such as the propionate
  • Triamcinolon or ethers and/or thereof such as the acetonide or the acetonide-21-N-benzoyl-2-methyl- ⁇ -alaninate or the acetonide-21-(3,3-dimethylbutyrate)
  • the invention relates to a pharmaceutical compositions for dermal use which contain at least one vitamin D or vitamin D analogue and at least one corticosteroid and which exhibits a higher efficacy in the treatment of psoriasis and other inflammatory skin diseases in humans and other mammals than any of the pharmacologically active components used alone.
  • Said efficacy is preferably measured as percentage change in PASI score in psoriasis and related skin diseases, such as sebo-psoriasis and seborrhoic dermatitis.
  • PASI Psoriasis Area and Severity Index
  • R score for redness
  • T score for thickness
  • S score for scaliness
  • E score for extent where the score is assessed according to a scale from 0 to 4 as follows:
  • FIG. 1 is a graphic illustration of the percentage change in PASI score obtained during 4 weeks of clinical trial where the efficacy of a preparation according to the invention containing calcipotriol hydrate (52.2 ⁇ g/g) and betamethasone dipropionate (0.643 mg/g) is compared to that of a preparation in the same vehicle containing only calcipotriol hydrate (52.2 ⁇ g/g) and a preparation in the same vehicle of betamethasone dipropionate (0.643 mg/g).
  • FIG. 1 shows an efficacy of the preparation of the invention which by far exceeds the efficacy obtainable by the two single component preparations.
  • FIG. 2 is a table showing the figures for percentage change in PASI score at each visit and end of treatment for the same clinical trial as described for FIG. 1 .
  • FIG. 3 is a bar diagram showing percentage of responders as a result of investigators' assessment of overall efficacy at each visit and end of treatment in the same clinical trial as for FIG. 1 .
  • Responders are defined as patients with marked improvement or clearance.
  • FIG. 4 is a table showing the figures for percentage of responders as a result of investigators' assessment of overall efficacy at each visit and end of treatment, cf. FIG. 3, in the same clinical trial as for FIG. 1 .
  • the invention provides a topical pharmaceutical composition in the form of an ointment, a cream, a lotion, preferably a scalp lotion, a liniment or other spreadable liquid or semi liquid preparation which is, preferably, non-aqueous or in the form of an oil-in-water or water-in-oil emulsion.
  • the composition of the invention is a mono-phase composition, i.e. a composition comprising a single solvent system, such as an ointment.
  • the invention provides a non-aqueous pharmaceutical composition for dermal use, said composition comprising
  • a first pharmacologically active component A consisting of at least one vitamin D analogue:
  • a second pharmacologically active component B consisting of at least one corticosteroid
  • the difference between the optimum stability pH of a first pharmacologically active component A and the optimum stability pH of a second pharmacologically active component B being at least 1;
  • At least one solvent component C selected from the group consisting of:
  • the maximum difference in optimum stability pH between the pharmacologically active compounds is at least 1.5, more preferred at least 2, in particular at least 2.5, more particularly at least 3, especially at least 4, such as at least 5.
  • the factor x (which designates the number of the units within the parentheses) is in the range 4-50, more preferably 4-40, in particular 4-30, especially 5-25, more especially 10-20, such as about 15. It is further preferred that R 1 ⁇ is CH 3 .
  • said component C is selected from compounds of the general formula H(OCH 2 C(R 1 )H) x OR 2 (II) where R 1 , x, and R 2 are as defined above, and mixtures thereof.
  • Arlamol E polyoxyethylene(15) stearyl ether
  • Arlamol DoA diisooctyl ester of adipic acid
  • Arlasolve 200 Polyoxyethylene-20-isohexadecyl ether
  • Finsolv P polyoxypropylene-15-stearyl ether benzoate
  • Isopropylesters of straight or branched C 10 -C 18 alkanoic or alkenoic acids such as isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate and isopropyl monooleate;
  • Miglyol 840 Propylene glycol diester of caprylic and caprinic acid
  • compositions of the present invention may be prepared in accordance with methods well known to the person skilled in the field of pharmacy.
  • the non-aqueous compositions may be prepared by incorporating the components into a well known ointment or lotion base excipient such as white soft paraffin (also known as vaseline) or PlastibaseTM (a base prepared from polyethylene (average MW about 21,000) and paraffin liquid) or ESMA-PTM (a microcrystalline wax).
  • preparation of a composition according to the invention is typically performed by melting while soft paraffin, adding a solution (typically at a concentration in the range of 0.0005-2.5% w/w) of the vitamin D analog in the required amount of solvent component C, e.g.
  • Typical content ranges of the various components in the finished composition according to the invention are 0.005 to 0.1% w/w of the corticosteroid component B, from 0.0001 to 0.025% w/w of the vitamin D analog component A, and from 1 to 20% w/w of the solvent component C, the remainder typically being primarily base excipient such as the abovementioned white soft paraffin and/or paraffin oil.
  • the composition may also contain other commonly used additives such as antioxidants (e.g. ⁇ -tocopherol).
  • composition according to the invention provides the following therapeutic advantages in the treatment of skin diseases, such as psoriasis, sebo-psoriasis and related disorders, compared to the single compound therapy or combination therapy of the prior art:
  • composition according to the invention comprising calcipotriol and betamethasone resulted in a faster onset of healing and a more effective healing of plaques than patients treated with only one of the active compounds.
  • a composition combining a vitamin D analogue and a topical steroid provides synergy in the form of additional benefit to the patient apart from the direct therapeutic value of the active substances. It has been shown that the skin irritative side effects of a vitamin D analogue, such as calcipotriol, is alleviated by the simultaneous application of a steroid, such as betamethasone, onto psoriatic skin, an effect that is only attainable using a two-component or multi-component treatment regimen where a vitamin D analogue and a steroid cannot be applied simultaneously to affected skin due to incompatibility of the praparations.
  • a vitamin D analogue such as calcipotriol
  • Satisfactory medical treatment of skin disorders can be attained in a shorter period of time using the composition according to the invention resulting in a reduction of steroid side effects, such as skin atrophy and rebound.
  • steroid side effects such as skin atrophy and rebound.
  • even a milder acting steroid of group 1, such as hydrocortisone which is presently not administered for psoriasis treatment will be efficient in reducing or even eliminating the skin irritation which often follows calcipotriol treatment.
  • Instructions for treatment will be simpler when a single preparation is needed resulting in improved compliance for the patient and the possibility of efficient treatment of a much larger population of psoriasis patients.
  • Instructions for treatment will be simpler when a single preparation is needed resulting in improved safety for the patient.
  • the invention also relates to a preferred pharmaceutical preparation according to the invention which is especially useful for the treatment of psoriatic skin diseases which are complicated by additional fungal infections, and which further contains an anti-fungal agent selected, e.g., from the group consisting of miconazol, clotrimazol, terbinafin, ciclopirox, bifonazol, nystatin, ketoconazol, econazol, and amorolfine.
  • an anti-fungal agent selected, e.g., from the group consisting of miconazol, clotrimazol, terbinafin, ciclopirox, bifonazol, nystatin, ketoconazol, econazol, and amorolfine.
  • compositions according to the invention do not contain other therapeutically effective compounds selected from the group consisting of the xanthine derivatives pentoxifylline, propentofyllin, and torbafylline, or any other xanthine or xanthine derivative.
  • the invention also relates to a method of treatment of psoriasis and related skin diseases comprising topically administering an effective amount of a composition according to the invention to a patient in need of such treatment.
  • Said method preferably comprises topical administration once or twice daily of a medically sufficient dosage of said composition.
  • composition according to the invention preferably contains 0.001-5 mg/g or ml or more preferably 0.01-0.25 mg/g or ml of said component A and 0.05-0.1 mg/g or ml of said component B.
  • Betamethasone (0.5 g, in the form of 0.643 g of its dipropionate) in particulate form (99% ⁇ 15 ⁇ m) is dispersed in 30 g Paraffin Liquid to form Dispersion 1.
  • Dispersion 1as well as 20 mg ⁇ -tocopherol are added to the Calcipotriol-containing paraffin mixture of while stirring, after which the mixture is cooled to below 30° C. to give a composition according to the invention with the following composition:
  • 1 g of ointment contains: Betamethasone 0.5 mg (as dipropionate 0.643 mg) Calcipotriol 50 ⁇ g (as hydrate 52.2 ⁇ g) Paraffin, Liquid 30 mg Polyoxypropylene-15-Stearyl 50 mg Ether ⁇ -Tocopherol 20 ⁇ g White Soft Paraffin to make 1 g
  • the Calcipotriol was extracted from the preparation into a mixture of methanol and 0.01M diammonium hydrogenphosphate (70:30) and quantified under the following HPLC conditions: Column: about 125 mm ⁇ 4 mm (i.d.) stainless steel column with LiChrospher RP-18, 5 ⁇ m; mobile phase: acetonitrile-methanol-0.01 M aqueous ammonium phosphate pH 6 (20:50:30); flow: about 2 ml/min; detection: variable wavelength UV-detector set at 265 nm. Calcipotriol and the related substances were separated by the reverse phase HLPC-method described above; Column: Superspher RP-18, 4 ⁇ m; Flow: 1.2 ml/min. The quantitative content of Betamethasone Dipropionate was determined by HLPC.
  • Betamethasone Dipropionate was extracted from the preparation into a mixture of acetonitrile:water (50:55) and quantified under the following HPLC conditions: Column: About 125 mm ⁇ 4 mm (i.d.) stainless steel column packed with LiChrospher RP-18, 5 ⁇ m. Mobile phase: Acetonitrile: water (50:55). Flow: 2 ml/min. Detection: Variable wavelength UV-detector set at 240 nm. The related substances besides betamethasone were determined by a reverse phase HLPC-method analogous to the above. Betamethasone: Determined as above with the exception of the mobile phase: Acetonitrile/methanol/0.05M buffer pH7 (25:5:70).
  • Betamethasone- Calci- related Betamethasone related potriol substances dipropionate substances ⁇ g/g % mg/g % Start 50.0 1.6 0.63 1.2 25° C. 3 months 50.5 1.4 0.64 0.2 40° C. 1 month 48.0 2.1 0.64 0.6 3 months 49.7 1.8 0.64 0.2
  • the stability of Calcipotriol was compared to an similar ointment where propylene glycol was used as the solvent and lanolin used as an emulsifier.
  • the composition of the comparison ointment was the same as the above with respect to Calcipotriol and Betamethasone dipropionate, as well as 10% w/w propylene glycol,10% w/w anhydrous lanolin and 80% w/w White Soft Paraffin.
  • the comparison ointment was stored for 2.5 months at 5° C. and 40° C., respectively. Only the content of Calcipotriol-related substances was determined in the manner described above. The results are shown in Table 2.
  • 1 g contains:
  • Betamethasone (As Dipropionate 0.643 mg) 0.5 mg Calcipotriol (as Hydrate 52.2 ⁇ g) 50 ⁇ g Disodium Phosphate Dihydrate 2.5 mg Diazolidinyl Urea 3 mg Polyoxypropylene-15-Stearyl Ether (Arlamol ® E) 50 mg Isohexadecan (Arlamol ® HD) 200 mg Polyoxyethylene-2-Stearyl Ether (Brij ® 72) 30 mg Water, purified to make 1 g
  • Disodium Phosphate and 3 g Diazolidinyl Urea are dissolved in about 714 g water.
  • the solution is heated to 60-70° C. to obtain the water phase.
  • 30 g Polyoxyethylene-2-Stearyl Ether is melted together with 200 g Isohexadecan at 60-70° C. and a solution of 52.2 mg Calcipotriol Hydrate in 50 g Polyoxypropylene-15-Stearyl Ether is added to obtain the oil phase.
  • the two phases are mixed during homogenisation, 643 mg Betamethasone Dipropionate is dispersed into the mixture, and the lotion is cooled during mixing to room temperature.
  • the preparation is stable at 25° C. for >14 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US09/959,367 1999-04-23 2000-01-27 Pharmaceutical composition Expired - Lifetime US6753013B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900561 1999-04-23
DK199900561 1999-04-23
PCT/DK2000/000033 WO2000064450A1 (en) 1999-04-23 2000-01-27 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
US6753013B1 true US6753013B1 (en) 2004-06-22

Family

ID=8094933

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/959,367 Expired - Lifetime US6753013B1 (en) 1999-04-23 2000-01-27 Pharmaceutical composition

Country Status (30)

Country Link
US (1) US6753013B1 (cs)
EP (5) EP2455083B1 (cs)
JP (4) JP4426729B2 (cs)
KR (1) KR100694526B1 (cs)
CN (1) CN1173703C (cs)
AU (1) AU774600B2 (cs)
BG (1) BG65115B1 (cs)
BR (3) BR122012030846B8 (cs)
CA (1) CA2370565C (cs)
CY (5) CY1113967T1 (cs)
CZ (1) CZ303142B6 (cs)
DK (5) DK3146969T3 (cs)
ES (5) ES2674563T3 (cs)
HK (1) HK1045650B (cs)
HR (1) HRP20010779B1 (cs)
HU (1) HU230045B1 (cs)
IL (2) IL145983A0 (cs)
IS (1) IS6120A (cs)
LT (2) LT2915534T (cs)
ME (1) ME00298B (cs)
MX (1) MXPA01010676A (cs)
NO (1) NO329486B1 (cs)
NZ (1) NZ515142A (cs)
PL (1) PL199123B1 (cs)
PT (5) PT2915534T (cs)
RS (1) RS52182B (cs)
RU (1) RU2238734C2 (cs)
SI (3) SI1178808T1 (cs)
SK (1) SK287653B6 (cs)
WO (1) WO2000064450A1 (cs)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20050222104A1 (en) * 2000-09-18 2005-10-06 Applied Research Systems Ars Holding N.V. Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
US20050281750A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase
US20050281754A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Sprayable compositions comprising a combination of pharmaceutical active ingredients, an alcohol phase and an oily phase
US20050281850A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Cosmetic/dermatological inverse emulsions containing calcitriol and clobetasol 17-propionate
WO2006120682A2 (en) 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US20070020213A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
WO2007082533A1 (en) 2006-03-17 2007-07-26 Leo Pharma A/S Isomerisation of pharmaceutical intermediates
US20070249567A1 (en) * 2004-11-22 2007-10-25 Wisconsin Alumni Research Foundation 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
US20080081799A1 (en) * 2006-09-28 2008-04-03 Deluca Hector F 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US20080081800A1 (en) * 2006-09-28 2008-04-03 Deluca Hector F 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
EP1917072A2 (en) * 2005-06-01 2008-05-07 Stiefel Research Australia Pty Ltd Vitamin formulation
US20080138296A1 (en) * 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080161587A1 (en) * 2002-11-18 2008-07-03 Teva Pharmaceuticals Usa, Inc. Crystallization method for purification of calcipotriene
US20080167505A1 (en) * 2006-12-28 2008-07-10 Antonio Buxade Vinas Procedure to obtain calcipotriol hydrate
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents
US20080227759A1 (en) * 2007-03-15 2008-09-18 Derek Wheeler Topical composition
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US20080261925A1 (en) * 2006-12-29 2008-10-23 Margaret Clagett-Dame Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid
US20080312181A1 (en) * 2005-05-10 2008-12-18 Avikam Harel Composition and Methods for Skin Care
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US20100286101A1 (en) * 2009-05-07 2010-11-11 Jason Carbol Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US20110053898A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Topical composition comprising vitamin d analogue and corticosteroids
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10130640B2 (en) 2010-06-11 2018-11-20 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11439625B2 (en) 2016-03-14 2022-09-13 Avexxin As Combination therapy for proliferative diseases
US11691959B2 (en) 2013-01-29 2023-07-04 Avexxin As Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287653B6 (sk) 1999-04-23 2011-05-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Nevodná farmaceutická kompozícia na dermálne použitie
CA2423930C (en) 2000-10-27 2009-11-24 Leo Pharma A/S Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
FR2848454B1 (fr) * 2002-12-17 2007-03-30 Galderma Res & Dev Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
EP1854466A1 (en) * 2002-12-17 2007-11-14 Galderma Research & Development, S.N.C. Pharmaceutical composition comprising a combination of calcitriol and clobetasol propionate
DE60316724T2 (de) * 2002-12-17 2008-07-17 Galderma S.A. Pharmazeutische zusammensetzung enthaltend calcitriol und clobetasolpropionat
JP2004359585A (ja) * 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
AR045241A1 (es) * 2003-08-12 2005-10-19 Novartis Consumer Health Sa Composicion topica que comprende terbinafina e hidrocortisona
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005115403A2 (en) * 2004-05-26 2005-12-08 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
KR20070027587A (ko) * 2004-06-17 2007-03-09 갈데르마 소시에떼아노님 실리콘제, 코르티코스테로이드 및 비타민 ｄ 또는 이의유도체를 함유하는 건선 치료용 조성물
FR2871695B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
FR2871698B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
CA2567683A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase
DE602005003138T3 (de) * 2004-06-17 2011-07-14 Galderma S.A. Zusammensetzung in sprayform mit einer kombination aus clobetasolpropionat und calcitriol, einer alkoholphase und ölphase
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
FR2871693B1 (fr) * 2004-06-17 2006-08-25 Galderma Sa Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis
JP2006131544A (ja) * 2004-11-05 2006-05-25 Medorekkusu:Kk 皮膚疾患治療用外用剤
FR2884419B1 (fr) * 2005-04-19 2007-06-22 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
WO2006111426A1 (en) * 2005-04-19 2006-10-26 Galderma S.A. Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
WO2010039251A1 (en) 2008-10-03 2010-04-08 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
CA3037273C (en) 2009-10-01 2022-05-03 Fredric Jay Cohen Orally administered corticosteroid compositions
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN103110648A (zh) * 2013-01-25 2013-05-22 江苏圣宝罗药业有限公司 钙泊三醇倍他米松软膏及其制备方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN104666312B (zh) * 2015-02-12 2017-11-07 重庆华邦制药有限公司 含有卡泊三醇和二丙酸倍他米松的制剂
MA41818A (fr) * 2015-03-27 2018-01-30 Leo Pharma As Timbre à micro-aiguilles pour administration d'un principe actif à la peau
TW201636025A (zh) * 2015-04-15 2016-10-16 Maruho Kk 皮膚用之醫藥組成物
KR101641372B1 (ko) * 2015-05-08 2016-07-20 (주)동구바이오제약 안정성과 피부투과율이 향상된 약학 조성물
CN107157919B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的半固体制剂的制备方法
CN107157920B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种包含维生素d或其衍生物的半固体制剂的制备方法
CN107157917B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的软膏的制备方法
CN107157918B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于银屑病治疗的半固体制剂的制备方法
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2019072353A1 (en) * 2017-10-11 2019-04-18 Elmasry Mohamed Zakria Ahmed Ali TOPICAL PHARMACEUTICAL PREPARATION OF BETAMETHASONE, CALCIPOTRIOL AND ROSE OIL FOR THE TREATMENT OF PSORIASIS
FR3083701B1 (fr) 2018-07-13 2020-08-14 Gifrer Barbezat Liniment oleo-alcalin
JP7350985B2 (ja) * 2020-03-19 2023-09-26 シオノギヘルスケア株式会社 ベタメタゾン吉草酸エステル含有組成物
CN115177586A (zh) * 2022-08-31 2022-10-14 江苏知原药业股份有限公司 一种卡泊三醇组合物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129003A2 (en) 1983-03-22 1984-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US4794106A (en) * 1983-01-31 1988-12-27 Taisho Pharmaceutical Co., Ltd. Cream
US4981845A (en) * 1988-09-09 1991-01-01 Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. Cosmetic composition
WO1991012807A1 (en) 1990-03-01 1991-09-05 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-d analogues in the treatment of acne
US5087620A (en) 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
EP0544391A1 (en) 1991-09-02 1993-06-02 Teva Pharmaceutical Industries, Ltd. Compositions for topical treatment of psoriasis and atopic dermatitis
WO1994014453A1 (en) 1992-12-23 1994-07-07 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Hydroxy vitamin d3 compounds for treating skin atrophy
WO1994015912A1 (en) 1993-01-15 1994-07-21 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) New crystalline form of a vitamin d analogue
US5827520A (en) * 1995-10-23 1998-10-27 L'oreal Vehicle and composition containing this vehicle and a stabilized cosmetic or dermatological active substance
US5854246A (en) * 1994-09-01 1998-12-29 Janssen Pharmaceutica, N.V. Topical ketoconazole emulsions
US5886038A (en) 1998-03-24 1999-03-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB892127A (en) 1958-03-03 1962-03-21 Merck & Co Inc Therapeutic preparations comprising steroids and vitamin d
DK116528A (cs) * 1966-09-30
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JP2522962B2 (ja) * 1986-09-19 1996-08-07 中外製薬株式会社 乾癬治療剤
US4847071A (en) 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US5185150A (en) 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
GB9314400D0 (en) * 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
JPH07173053A (ja) * 1993-12-20 1995-07-11 Otsuka Pharmaceut Co Ltd 抗微生物剤
JP3506474B2 (ja) 1994-01-07 2004-03-15 帝人株式会社 安定性の向上した乾癬治療剤
US5840925A (en) * 1995-06-29 1998-11-24 Hauser, Inc. Trioxane dimer compounds having antiproliferative and antitumor activities
JPH11514999A (ja) * 1995-10-10 1999-12-21 ストルーブ，マリリン ビタミンｄおよびその誘導体による掻痒症治療
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
JPH1067757A (ja) * 1996-06-21 1998-03-10 Ss Pharmaceut Co Ltd トリアゾール誘導体またはその塩
JPH10139669A (ja) * 1996-11-05 1998-05-26 Teijin Ltd 脂漏性角化症治療剤
US6100294A (en) * 1997-05-16 2000-08-08 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH) 3-epi-vitamin D3 compounds and uses thereof
EP0981514B1 (en) * 1997-05-16 2006-04-05 Woman & Infants Hospital 3-epi vitamin d2 compounds and uses thereof
EP1051974A4 (en) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd LOTIONS CONTAINING VITAMIN D 3 DERIVATIVES
WO1999029326A1 (fr) * 1997-12-09 1999-06-17 Chugai Seiyaku Kabushiki Kaisha Emulsions contenant des derives de vitamine d¿3?
JPH11188054A (ja) * 1997-12-25 1999-07-13 Lion Corp 皮膚外用部材
JPH11246329A (ja) * 1998-02-27 1999-09-14 Shiseido Co Ltd 皮膚外用剤
ES2245511T3 (es) * 1998-03-04 2006-01-01 Teijin Limited Lociones de vitamina d3 activa en forma de emulsion.
SK287653B6 (sk) 1999-04-23 2011-05-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Nevodná farmaceutická kompozícia na dermálne použitie

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794106A (en) * 1983-01-31 1988-12-27 Taisho Pharmaceutical Co., Ltd. Cream
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
EP0129003A2 (en) 1983-03-22 1984-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol
US4981845A (en) * 1988-09-09 1991-01-01 Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. Cosmetic composition
WO1991012807A1 (en) 1990-03-01 1991-09-05 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-d analogues in the treatment of acne
US5087620A (en) 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
EP0544391A1 (en) 1991-09-02 1993-06-02 Teva Pharmaceutical Industries, Ltd. Compositions for topical treatment of psoriasis and atopic dermatitis
WO1994014453A1 (en) 1992-12-23 1994-07-07 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Hydroxy vitamin d3 compounds for treating skin atrophy
WO1994015912A1 (en) 1993-01-15 1994-07-21 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) New crystalline form of a vitamin d analogue
US5854246A (en) * 1994-09-01 1998-12-29 Janssen Pharmaceutica, N.V. Topical ketoconazole emulsions
US5827520A (en) * 1995-10-23 1998-10-27 L'oreal Vehicle and composition containing this vehicle and a stabilized cosmetic or dermatological active substance
US5886038A (en) 1998-03-24 1999-03-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Database STN Intern. File Caplus [On line]; Glade C P et al: Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of" retrieved from CAPLUS, accession No. 1996:599855. Database accession No. 125:266250 XP002900974 abstract * BR. J. Dermatol., vol. 135, No. 3, 1996, pp. 379-384.
Bazek et al., Nouv. Dermatol., vol. 13, No. 10, pp. 746-751 (1994) (with English translation).
CAPlus AN: 1985:27554 English abstract of Veverka, CS 214078, 1982.* *
Gennaro Remington's Pharmaceutical Sciences, 18th ed., p. 1310.* *
Kragballe et al., British Journal of Dermatology, vol. 139, pp. 649-654 (1998).
Richards et al., J. Am. Acad Dermatol., vol. 41, No. 4, pp. 581-583 (Oct. 1999).
Ruzick et al.., British Journal of Dermatology 1998; 139: 254-258.* *
Ruzicka et al: "Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks'treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, doucle-blind, randomized study" British Journal of Dermatology, vol. 138, 1998, pp. 254-258, XP002900975 pp. 257.

Cited By (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US20050222104A1 (en) * 2000-09-18 2005-10-06 Applied Research Systems Ars Holding N.V. Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20070020213A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US20080138296A1 (en) * 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080161587A1 (en) * 2002-11-18 2008-07-03 Teva Pharmaceuticals Usa, Inc. Crystallization method for purification of calcipotriene
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20050281754A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Sprayable compositions comprising a combination of pharmaceutical active ingredients, an alcohol phase and an oily phase
US20050281850A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Cosmetic/dermatological inverse emulsions containing calcitriol and clobetasol 17-propionate
US20050281750A1 (en) * 2004-06-17 2005-12-22 Galderma S.A. Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase
US7713952B2 (en) * 2004-11-22 2010-05-11 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
US20070249567A1 (en) * 2004-11-22 2007-10-25 Wisconsin Alumni Research Foundation 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses
WO2006120682A2 (en) 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US8034788B2 (en) 2005-05-10 2011-10-11 Dermipsor Ltd. Composition and methods for skin care
US20090131488A1 (en) * 2005-05-10 2009-05-21 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US20080312181A1 (en) * 2005-05-10 2008-12-18 Avikam Harel Composition and Methods for Skin Care
US9603861B2 (en) 2005-05-10 2017-03-28 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8298515B2 (en) 2005-06-01 2012-10-30 Stiefel Research Australia Pty Ltd. Vitamin formulation
EP1917072A4 (en) * 2005-06-01 2010-10-13 Stiefel Res Australia Pty Ltd VITAMIN PREPARATION
US8629128B2 (en) 2005-06-01 2014-01-14 Stiefel West Coast, Llc Vitamin formulation
EP1917072A2 (en) * 2005-06-01 2008-05-07 Stiefel Research Australia Pty Ltd Vitamin formulation
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
WO2007082533A1 (en) 2006-03-17 2007-07-26 Leo Pharma A/S Isomerisation of pharmaceutical intermediates
US20120046253A1 (en) * 2006-08-29 2012-02-23 Teva Pharmaceutical Industries Ltd. STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY
EP2056791A2 (en) * 2006-08-29 2009-05-13 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions including vitamin d and corticosteroid
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
US7741314B2 (en) * 2006-09-28 2010-06-22 Wisconsin Alumni Research Foundation 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US20080081800A1 (en) * 2006-09-28 2008-04-03 Deluca Hector F 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US20080081799A1 (en) * 2006-09-28 2008-04-03 Deluca Hector F 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US8114859B2 (en) * 2006-09-28 2012-02-14 Wisconsin Alumni Research Foundation 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080167505A1 (en) * 2006-12-28 2008-07-10 Antonio Buxade Vinas Procedure to obtain calcipotriol hydrate
US7507865B2 (en) * 2006-12-28 2009-03-24 Laboratorios Vinas, S.A. Method for obtaining calcipotriol hydrate
US8404667B2 (en) 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US20110195941A1 (en) * 2006-12-29 2011-08-11 Margaret Clagett-Dame Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid
US20080261925A1 (en) * 2006-12-29 2008-10-23 Margaret Clagett-Dame Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid
US20190358151A1 (en) * 2007-03-15 2019-11-28 Drug Delivery Solutions Limited Topical composition
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US11065195B2 (en) * 2007-03-15 2021-07-20 MC2 Therapeutics Limited Topical composition
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US20080227759A1 (en) * 2007-03-15 2008-09-18 Derek Wheeler Topical composition
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US20100286101A1 (en) * 2009-05-07 2010-11-11 Jason Carbol Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
WO2010129062A1 (en) * 2009-05-07 2010-11-11 Jason Carbol Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US20110053898A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Topical composition comprising vitamin d analogue and corticosteroids
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US10682364B2 (en) 2010-06-11 2020-06-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US10688108B2 (en) 2010-06-11 2020-06-23 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10660908B2 (en) 2010-06-11 2020-05-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10716799B2 (en) 2010-06-11 2020-07-21 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10617698B2 (en) 2010-06-11 2020-04-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US10130640B2 (en) 2010-06-11 2018-11-20 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US10154959B1 (en) 2011-03-14 2018-12-18 Drug Delivery Solutions Limited Ophthalmic composition containing a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US11691959B2 (en) 2013-01-29 2023-07-04 Avexxin As Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
US11439625B2 (en) 2016-03-14 2022-09-13 Avexxin As Combination therapy for proliferative diseases
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Also Published As

Publication number Publication date
KR20010110803A (ko) 2001-12-13
JP2015155451A (ja) 2015-08-27
MXPA01010676A (es) 2003-08-20
DK3146969T3 (en) 2018-08-27
EP1178808A1 (en) 2002-02-13
EP1178808B2 (en) 2019-06-12
SI3146969T1 (en) 2018-08-31
EP2450043B1 (en) 2016-08-17
CY1120313T1 (el) 2019-07-10
ES2388425T5 (es) 2020-02-12
SI2915534T1 (sl) 2018-10-30
EP3146969A1 (en) 2017-03-29
MEP39108A (en) 2011-02-10
PT2915534T (pt) 2018-06-20
HUP0200879A3 (en) 2004-04-28
JP2002542293A (ja) 2002-12-10
EP2455083A1 (en) 2012-05-23
BR122012030847B1 (pt) 2021-07-06
HK1045650A1 (en) 2002-12-06
YU75701A (sh) 2005-07-19
JP4426729B2 (ja) 2010-03-03
BRPI0009956B1 (pt) 2014-11-11
JP2008297309A (ja) 2008-12-11
CN1351499A (zh) 2002-05-29
JP2013075923A (ja) 2013-04-25
CA2370565A1 (en) 2000-11-02
PT2455083E (pt) 2013-10-09
IL145983A0 (en) 2002-07-25
SK287653B6 (sk) 2011-05-06
HUP0200879A2 (en) 2002-08-28
DK2455083T3 (da) 2013-09-30
JP5721926B2 (ja) 2015-05-20
BG106030A (en) 2002-05-31
DK1178808T3 (da) 2012-07-30
NO20015175D0 (no) 2001-10-23
CA2370565C (en) 2008-11-25
CN1173703C (zh) 2004-11-03
RU2238734C2 (ru) 2004-10-27
CY1114420T1 (el) 2016-08-31
EP3146969B1 (en) 2018-06-20
ES2388425T3 (es) 2012-10-15
DK2915534T3 (en) 2018-06-14
EP2915534A1 (en) 2015-09-09
CZ303142B6 (cs) 2012-05-02
CZ20013739A3 (cs) 2002-06-12
PT1178808E (pt) 2012-08-16
BRPI0009956A (pt) 2002-01-08
NO329486B1 (no) 2010-10-25
AU774600B2 (en) 2004-07-01
NZ515142A (en) 2004-01-30
PT2450043T (pt) 2016-10-12
IS6120A (is) 2001-10-22
LT2915534T (lt) 2018-06-25
PL351387A1 (en) 2003-04-07
EP2915534B1 (en) 2018-03-14
JP5886999B2 (ja) 2016-03-16
CY1120659T1 (el) 2019-12-11
PL199123B1 (pl) 2008-08-29
HU230045B1 (hu) 2015-06-29
DK1178808T4 (da) 2019-09-02
CY1118206T1 (el) 2017-06-28
EP1178808B1 (en) 2012-05-30
ES2674563T3 (es) 2018-07-02
HK1045650B (zh) 2005-04-08
SI1178808T1 (sl) 2012-10-30
HRP20010779A2 (en) 2002-12-31
KR100694526B1 (ko) 2007-03-13
SK15182001A3 (sk) 2002-06-04
ES2671785T3 (es) 2018-06-08
BRPI0009956B8 (pt) 2021-07-06
DK2450043T3 (en) 2016-09-12
NO20015175L (no) 2001-10-23
IL145983A (en) 2006-08-20
WO2000064450A1 (en) 2000-11-02
PT3146969T (pt) 2018-10-18
EP2455083B1 (en) 2013-09-18
RS52182B (sr) 2012-10-31
CY1113967T1 (el) 2016-07-27
EP2450043A1 (en) 2012-05-09
ES2432691T3 (es) 2013-12-04
BR122012030846B1 (pt) 2021-04-27
BR122012030846B8 (pt) 2021-05-25
AU2278300A (en) 2000-11-10
ES2602450T3 (es) 2017-02-21
LT3146969T (lt) 2018-09-25
ME00298B (me) 2011-05-10
BG65115B1 (bg) 2007-03-30
HRP20010779B1 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
US6753013B1 (en) Pharmaceutical composition
US6787529B2 (en) Topical composition
AU2001291637A1 (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid

Legal Events

Date Code Title Description
AS Assignment

Owner name: LEO PHARMACEUTICAL PRODUCTS LTD. A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DIDRIKSEN, ERIK;HOY, GERT;REEL/FRAME:012315/0869

Effective date: 20011001

STCF Information on status: patent grant

Free format text: PATENTED CASE

RR Request for reexamination filed

Effective date: 20060717

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

B1 Reexamination certificate first reexamination

Free format text: CLAIMS 3, 9, 10, 13, 15, 20 AND 22 ARE CANCELLED.CLAIMS 1, 4-5, 7-8, 11-12, 14, 17-19, 21 AND 23 ARE DETERMINED TO BE PATENTABLE AS AMENDED.CLAIMS 2, 6 AND 16, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE.NEW CLAIMS 24-80 ARE ADDED AND DETERMINED TO BE PATENTABLE.

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 12